Friday 6 November 2026 Export ELOX’s income statement to Excel — free account

Senesco Technologies Inc.

ELOX Healthcare Biotechnology

Senesco Technologies Inc.’s revenue for fiscal 2024 (year ended December 2024) was $6.4 million.

EPS: +93.5%
Free cash flow: −144.3%

Quarter to June 2026, against a year earlier

Revenue growth 10 yrs

12.44 0.36 −2.81%

Follow ELOX

Alert me

Market cap: $51.7M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 62.29%

Capital & Financial Ratios $m

Size

Market Cap 51.66

Revenue ttm —

Net income ttm (10.15)

Free cash flow ttm (10.79)

Net debt Q (61.97)

Valuation

P/E 0.00

Forward P/E —

Price / sales 0.00

Forward P/S Powerpack

Price / FCF 0.00

Price / book 1.82

Financial health

Current ratio Q 3.74

Debt / equity Q 0.00

Interest coverage Q (22,105.00)

Growth

Revenue growth Q —

Operating income growth Q −10.48%

EPS, this year —

EPS, next year A —

Revenue, next year A —

EPS, past 5 yrs —

EPS, next 5 yrs A —

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

P/B against its own 10 years 9.60%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	1	0	5	62
Receivables	—	3	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	2	3	5	63

	2023	2024	2025	Q'26
Payables	6	5	3	3
ST’ Debt	2	7	1	—
Other	13	13	12	12
	23	27	17	17

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY23 Estimate −21.67 Actual −14.41

−35.41 −29.47 −23.54 −17.61 −11.67

Q4 FY22 Beat +0.55

Q1 FY23 Miss −3.63

Q2 FY23 Miss −4.62

Q3 FY23 Beat +7.26

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q4 FY22	−32.67	−32.12	Beat by 0.55
Q1 FY23	−28.05	−31.68	Miss by 3.63
Q2 FY23	−16.94	−21.56	Miss by 4.62
Q3 FY23	−21.67	−14.41	Beat by 7.26

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.88)	(0.66)	—	—	—
’25	(4.94)	(5.45)	—	—	(5.34)
’24	—	—	—	—	(9.20)
’23	(31.68)	(21.56)	(14.41)	(10.07)	(72.98)
’22	(57.21)	(52.80)	(39.60)	(32.12)	(183.17)
’21	(96.81)	(237.62)	(48.40)	(61.61)	(418.04)
’20	(154.01)	(88.01)	(70.41)	(66.01)	(378.44)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’24	—	—	—	—	6

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(5)	(5)	—	—	—
’25	1	(2)	—	—	(6)
’24	—	—	—	—	(5)
’23	(7)	(2)	(3)	(2)	(14)
’22	(9)	(10)	(7)	(6)	(32)
’21	(8)	(10)	(8)	(10)	(35)
’20	(12)	(6)	(5)	(5)	(28)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(5)	(5)	—	—	—
’25	1	(2)	—	—	(6)
’24	—	—	—	—	(5)
’23	(7)	(2)	(3)	(2)	(14)
’22	(10)	(10)	(7)	(6)	(32)
’21	(8)	(10)	(8)	(10)	(35)
’20	(12)	(6)	(5)	(5)	(28)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	0	—	—	—	—	—	—	—	6	—	—		+74.2%	—	—	—	—
	Gross margin, %	100.00	—	—	—	—	—	—	—	100.00	—	—		0.0 pt	Powerpack Senesco Technologies Inc.’s next three years, line by line See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(10)	(21)	(47)	(51)	(35)	(67)	(36)	(17)	(3)	(6)	(12)		(5.4%)
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	(49.43)	0.00	0.00		0.0 pt
	Net income	(10)	(21)	(47)	(51)	(35)	(67)	(36)	(17)	(3)	(6)	(10)		(5.4%)
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	18.61	0.00	0.00		n/m
	Earnings	(1,030.47)	(2,088.25)	(638.06)	(589.66)	(378.44)	(418.04)	(183.17)	(73.37)	(9.20)	(5.34)	(11.93)		(44.3%)
	Cash flow	(921.25)	(1,408.94)	(425.60)	(455.39)	(308.84)	(220.13)	(161.73)	(61.36)	(13.80)	(5.64)	(1.59)		(43.2%)
	Capex	(3.75)	(20.95)	(3.11)	(0.44)	0.00	(0.56)	(0.34)	1.32	0.11	0.00	0.00		n/m
	Free cash flow	(925.00)	(1,429.89)	(428.71)	(455.83)	(308.84)	(220.69)	(162.07)	(60.04)	(13.69)	(5.64)	(1.59)		(43.3%)
	Book value	0.00	1,888.69	582.24	418.65	112.17	140.78	(54.14)	(96.70)	(71.22)	(10.61)	6.84		n/m
	Shares, m	0	0	0	0	0	0	0	0	0	1	3		+69.7%
Valuation, ×
Valuation, ×	P/E	0.00	—	—	—	—	—	—	—	0.00	—	0.00		0.0
	P/S	0.00	—	—	—	—	—	—	—	0.00	—	0.00		0.0
	P/B	10.19	—	—	—	—	—	—	—	0.00	—	1.82		5.1
	EV/Sales	0.00	—	—	—	—	—	—	—	0.00	—	0.00		0.0
	EV/FCF	(3.18)	—	—	—	—	—	—	—	(0.18)	—	(2.41)		(1.7)
Cash, $m
Cash, $m	Operating cash flow	(9)	(16)	(31)	(39)	(28)	(35)	(32)	(14)	(5)	(6)	(11)		(3.7%)
	Capex	0	0	0	0	—	0	0	0	0	0	0		n/m
	Free cash flow	(9)	(16)	(32)	(39)	(28)	(35)	(32)	(14)	(5)	(6)	(11)		(3.7%)
Balance, $m
Balance, $m	Working capital	1	21	43	46	16	34	(3)	(21)	(24)	(12)	46		n/m
	Net debt	(1)	(24)	(49)	(41)	(13)	(31)	(7)	2	6	(4)	(62)		+18.7%
	Shareholders’ equity	5	21	43	36	10	22	(11)	(23)	(24)	(12)	46		n/m
Returns, %
Returns, %	ROA	(237.31)	(154.22)	(124.99)	(92.78)	(80.95)	(186.35)	(108.86)	(149.37)	(134.09)	(145.40)	(34.15)		+91.9 pt
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		0.0 pt
	ROE	0.00	(212.48)	(146.83)	(128.59)	(148.90)	(409.19)	(615.23)	102.55	13.39	33.08	(89.91)		+33.1 pt
People
People	Employees	5	15	29	29	20	25	15	—	—	7	—		+3.8%
	Revenue/emp, $m	0.02	0.00	0.00	0.00	0.00	0.00	0.00	—	0.00	0.00	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2024 · latest quarter Dec 2015 · fundamentals updated 26 Oct 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
HRTX Heron Therapeutics, Inc.	$53.2M	— (loss-making)	— (loss-making)	+1.25% (above 0%: growing)	n/m	+78.75% (above 0%: growing)	69.28%	(5.43%)	Compare
VRCA Verrica Pharmaceuticals Inc.	$53.1M	— (loss-making)	— (loss-making)	−53.85% (below 0%: shrinking)	n/m	+7.63% (above 0%: growing)	85.02%	(223.42%)	Compare
RNTX Rein Therapeutics Inc.	$52.8M	— (loss-making)	—	—	n/m	−34.62% (below 0%: shrinking)	0.00%	0.00%	Compare
ALPS Alps Group Inc.	$52.3M	— (loss-making)	—	—	n/m	−26.48% (below 0%: shrinking)	—	0.00%	Compare
ELOX Senesco Technologies Inc.	$51.7M	— (loss-making)	—	—	n/m	−144.34% (below 0%: shrinking)	100.00%	0.00%
KLRS Kalaris Therapeutics Inc.	$51.6M	— (loss-making)	—	—	n/m	+11.91% (above 0%: growing)	0.00%	0.00%	Compare
INKT MiNK Therapeutics, Inc.	$51.3M	— (loss-making)	—	—	n/m	−32.73% (below 0%: shrinking)	0.00%	0.00%	Compare
OSTX OS Therapies Incorporated	$51.3M	— (loss-making)	—	—	n/m	−134.43% (below 0%: shrinking)	—	0.00%	Compare
PLRX Pliant Therapeutics, Inc.	$50.5M	— (loss-making)	— (loss-making)	−95.03% (below 0%: shrinking)	n/m	+68.61% (above 0%: growing)	0.00%	0.00%	Compare
Median of peers	$51.9M	—	—	−53.85%	—	−9.42%	0.00%	0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 28 April 2023

Ownership

Directors and executive officers, together 20.20%

Tomer Kariv 17.00%

Pontifax Funds 16.90%

Gurnet Point L.P. 5.70%

Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement